Security key
92790C104
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN)
CUSIP: 92790C104
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, $0.01 par value per share
- Total 13F shares
- 69,645,524
- Total 13F value
- $906,163,827
- Share change
- -1,181,668
- Put/Call ratio
- 176%
- SEC-reported price per share
- $13.01
- Number of holders
- 137
- Value change
- -$23,346,202
- Number of buys
- 86
- Number of sells
- 44
- Shares outstanding
- 110,466,431
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
137
Top holders
10
VRDN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Viridian Therapeutics, Inc.\DE SEC filings
Viridian Therapeutics, Inc.\DE company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92790C104
Recent filing periods:
Ownership snapshot
Top reported holders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F
Lead comparable stake: 8.5%
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 8.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
8.5%
Paradigm Biocapital Advisors LP
4.6%
STATE STREET CORP
4.1%
Venrock Adviser, LLC
3.5%
BlackRock Finance, Inc.
3.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
Company
|
8.5%
|
$164,859,014
9,415,135 shares
|
— | 31 Mar 2024 |
| Paradigm Biocapital Advisors LP |
13F
Company
|
4.6%
|
$88,100,164
5,031,420 shares
|
— | 31 Mar 2024 |
| STATE STREET CORP |
13F
Company
|
4.1%
|
$78,595,649
4,488,615 shares
|
— | 31 Mar 2024 |
| Venrock Adviser, LLC |
13F
Company
|
3.5%
|
$67,985,569
3,882,671 shares
|
— | 31 Mar 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
3.5%
|
$66,759,152
3,812,630 shares
|
— | 31 Mar 2024 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
3.3%
|
$64,035,803
3,657,099 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
137
Shares
69,645,524
Rows available
137
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
134
Q2 2024 holders
137
Holder diff
3
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend